MOMO'S BREAKOUT BOARD

[brian39]

Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move quickly with very little volume (only 24,000,000 shares). Multiple grants in the millions to cover research and testing costs without dilution of stock and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing plus royalties to sell hormone free contraception drug Ovaprene in the USA after FDA approval. Dare-BV-1 was just put on Fast Track in yesterday’s news and has a cure rate of 86% vs. current FDA approved products that range from 37-68% cure rate. Company will look to partner up with a deal similar to the Bayer deal. Stock is trading around $1.00 with potential to soar with additional grants, partnerships, and FDA approvals.